GLP-1 Medications – What Personal Trainers Need to Know

REFERENCES

1. Alfadda, AA, Al-Naami, MY, Masood, A, Elawad, R, Isnani, A, Ahamed, SS, and Alfadda, NA. Long-term weight outcomes after bariatric surgery: A single center Saudi Arabian cohort experience. Journal of Clinical Medicine 10(21): 4922, 2021.
2. Ard, J, Fitch, A, Fruh, S, and Herman, L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide-1 receptor agonists. Advances in Therapy 38: 2821-2839, 2021.
3. Beck, B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 361(1471): 1159-1185, 2006.
4. Bode, B. Design, findings and implications of the liraglutide phase III clinical trial program. Clinical Investigation 2(1): 59-72, 2012
5. Drucker, D. The GLP-1 journey from discovery science to therapeutic impact. Journal of Clinical Investigation 134(2): e175634, 2024.
6. Efendic, S, and Portwood, N. Overview of incretin hormones. Hormone and Metabolic Research 36(11-12): 742-746, 2004.
7. Hall, S, Isaacs, D, and Clements, JN. Pharmacokinetics and clinical implications of semaglutide: A new glucagon-like peptide (GLP)-1 receptor agonist. Clinical Pharmacokinetics 57(12): 1529-1538, 2018.
8. Hathaway, JT, Shah, MP, Hathaway, DB, Zekavat, SM, Krasniqi, D, Gittinger Jr., JW, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology 142(8): 732-739, 2024.
9. Iqbal, J, Wu, H-X, Hu, N, Zhou, Y-H, Xiao, F, Wang, T, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials. Obesity Reviews 23(6): e13435, 2022.
10. Lopez, P, Taaffe, DR, Galvão, DA, Newton, RU, Nonemacher, ER, Wendt, VM, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: A systematic review and meta-analysis. Obesity Reviews 23(5): e13428, 2023.
11. O’Brien, PE, Hindle, A, Brennan, L, Skinner, S, Burton, P, Smith, A, Crosthwaite, G, and Brown, W. Long-term outcomes after bariatric surgery: A systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obesity Surgery 29(1): 3-14, 2019.
12. Padwal, R, Li, SK, and Lau, DC. Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews 3: 2004.
13. Rubino, D, Abrahamsson, N, Davies, M, Hesse, D, Greenway, FL, Jensen, C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. Journal of the American Medical Association 325(14): 1414-1425, 2021.
14. Sodhi, M, Rezaeianzadeh, R, Kezouh, A, and Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Journal of the American Medical Association 330(18): 1795-1797, 2023.
15. Wharton, S, Blevins, T, Connery, L, Rosenstock, J, Raha, S, Liu, R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine 389(10): 877-888, 2023.
16. Wilding, JPH, Batterham, RL, Davies, M, Van Gaal, LF, Kandler, K, Konakli, K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism 24(8): 1553-1564, 2022.
17. Wilding, JPH, Batterham, RL, Calanna, S, Davies, M, Van Gaal, LF, Lingvay, I, et al. Once-weekly semaglutide in adults with overweight or obesity. Diabetes, Obesity and Metabolism 384(11): 989–1002, 2021.

Learn about the benefits of NSCA Membership »